Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121

Video

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

In a study of 21 patients, bb2121 was generally well tolerated with an objective response rate of 94% and a partial response rate or better of 89%. The first dose level was therapeutic, so 3 patients had a transient response and progressed very quickly, said Berdeja. After that, all but 1 patient had a response that was durable at the 150 mg dose.

Overall response in patients treated at the therapeutic dose levels was 94% with a 56% complete response rate, and the responses continue to improve with time, Berdeja adds. The therapy is working so quickly in fact, that it is inducing a complex assessment in myeloma because the tumor cells are being killed, but then the pair of proteins that are required to become negative are lagging, Berdeja explains. Additionally, minimal residual disease negativity is being seen in patients.

The FDA granted bb2121 a breakthrough therapy designation in November of 2017, based on preliminary clinical data from the ongoing phase I CRB-401 study.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.